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Background: Patients with advanced cancer, particularly of the
lung, frequently experience deteriorating physical health. Supportive
care measures help ensure optimal quality of life during difficult
psychologic and social situations. Research in the area of supportive
care in patients with cancer should be made a priority.
Methods: This review summarizes the findings from selected sup-
portive care studies presented at the recently concluded 46th annual
meeting of the American Society of Clinical Oncology.
Discussion: Topics discussed include the use of a single dose of
fosaprepitant for prevention of chemotherapy-induced nausea and
vomiting, statins to lower the incidence of venous thromboembolic
events, fentanyl pectin nasal spray for cancer-related pain, and a
closer look at the utilization of complementary and alternative
medicine in patients with cancer.
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Patients with advanced cancer in general and those withlung cancer in particular have to deal with deteriorating
physical health and adverse psychologic and social situations.
Symptom management and psychologic care are of paramount
importance in ensuring optimal quality of life.1 As many as 40%
of patients with cancer have unmet supportive care needs.2
Clearly, supportive care research in patients with cancer should
be made a priority. In this article, we report key advances in
supportive care presented at the 46th annual meeting of the
American Society of Clinical Oncology (ASCO).
NAUSEA AND VOMITING
Arguably, advances in the prevention and treatment of
chemotherapy-induced nausea and vomiting (CINV) repre-
sent one of the notable achievements in supportive care over
the past two decades.3
There are multiple 5-HT3 antagonists available for the
prevention and treatment of CINV. Agent selection is often
based on cost and availability. Palonosetron is a second
generation serotonin antagonist that has a significantly longer
halflife than the first generation serotonin antagonists. Ha-
toum et al. retrospectively evaluated claims data from 1692
adult patients with lung cancer treated with a cisplatin-based
chemotherapy regimen between 2005 and 2008. This study
was conducted to compare the risk of CINV associated with
a hospital or emergency room visit in patients receiving
palonosetron (390 patients) with that associated with any
other 5-HT3 antagonist-based regimen.4 Risk of CINV was
31% lower in palonosetron-treated patients than in those
receiving any other 5-HT3 antagonist-based regimen (odds
ratio  0.69, p  0.05), and these patients had shorter
hospital/emergency room stays associated with CINV (p 
0.02). By avoiding hospitalization, palonosetron could poten-
tially be more cost-effective than other 5-HT3 antagonists, but
further studies need to be done to confirm these observations.
The NK1 receptor antagonist, aprepitant, is the newest
addition to the armamentarium of antiemetics. Most of the
clinical data available is for its use in patients receiving
cisplatin or carboplatin. The efficacy of aprepitant in prevent-
ing nausea and vomiting in patients with oxaliplatin is not
known. Gralla et al.5 analyzed the benefit of adding aprepitant
to treatment naive patients receiving any platinum agent by
assessing 1872 patients who were enrolled in prospective
randomized phase III trials. All patients received ondansetron
and dexamethasone on day 1 and dexamethasone in the
delayed setting. Patients in the aprepitant groups received
aprepitant on days 1 to 3. Receiving aprepitant resulted in a
5-day no emesis odds ratio of 2.38 (95% confidence interval
[CI], 1.92–2.93) in the cisplatin group and 2.30 (95% CI,
1.15–4.63) in the carboplatin group, both of which were
statistically significant. In the oxaliplatin group, aprepitant
did result in an overall decrease in 5-day emesis with an odds
ratio of 1.45 (95% CI, 0.71–3.34); however, this was not
statistically significant. Aprepitant seems to be beneficial in
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treating emesis associated with platinum agents, although its
role in oxaliplatin-induced CINV is less clear.
Traditionally, aprepitant is given daily for three doses
starting on the day of chemotherapy. Fosaprepitant is the
intravenous formulation of aprepitant and is approved as a
substitution for day 1 oral aprepitant. In one of the most
provocative studies related to supportive care issues pre-
sented at ASCO this year, Grunberg et al.6 compared the
traditional 3-day dosing of aprepitant to a single 150 mg dose
of fosaprepitant on day 1 in patients receiving cisplatin
chemotherapy 70 mg/m2. The primary end point was ab-
sence of emesis and no rescue medication use. In this study
(noninferiority design) involving 2247 patients, 72.3% (95%
CI, 69.6–74.9) of those who received the 3-day oral aprepi-
tant and 71.9% (95% CI, 69.1–74.5) of those who received
only 1 day of fosaprepitant had a complete response. The
tolerability of fosaprepitant was similar to that of the 3-day
oral regimen with constipation and asthenia being the most
common adverse events in both groups. Based on these
results, single-dose fosaprepitant was found to be noninferior
to the 3-day regimen of aprepitant. Use of a single intrave-
nous dose of fosaprepitant would, therefore, be an option for
patients receiving platinum-based chemotherapy.
Olanzapine is an atypical antipsychotic that has been
used in the treatment of CINV but is not standard of care for
the first-line prevention of CINV. Navari et al.7 conducted a
phase III trial in 61 treatment naive patients receiving cispla-
tin or doxorubicin and cyclophosphamide, comparing a three-
drug aprepitant regimen and a three-drug olanzapine regimen
for the prevention of CINV. Patients in the olanzapine group
received olanzapine 10 mg orally daily on days 1 to 4,
palonosetron on day 1, and dexamethasone on day 1 of
chemotherapy. The patients in the aprepitant group received
3 days of aprepitant at the approved dose, palonosetron on
day 1, and dexamethasone on days 1 to 4. Overall CINV
prevention rates were similar at 77% in the olanzapine group
and 73% in the aprepitant group. Obviously, these findings
need to be confirmed in larger studies.
FATIGUE
Fatigue is one of the most common symptoms reported
by patients with cancer in general, and those with lung cancer
in particular, and is associated with the greatest adverse
impact on quality of life.8 Between 60 and 90% of all patients
with cancer experience significant fatigue at some point
throughout treatment.9 Neurophysiologic, immunologic, and
hormonal changes have all been implicated in the pathogen-
esis of cancer-related fatigue.10 In addition, select chemother-
apy agents are well recognized for their ability to cause
anemia and fatigue. Platinum analogs, taxanes, and pem-
etrexed, in particular, play a large role in the development of
cancer-related fatigue for patients with lung cancer.8
Bharne et al.11 conducted a study to examine biochem-
ical correlates of fatigue in patients with and without cancer.
One hundred ninety-five patients (133 with cancer and 62
without cancer) completed a screening tool designed to assess
problems including fatigue, sleep, and mood disturbance.
Sixty-one percent of patients reported problems with fatigue,
with no significant difference in the proportion of cancer and
noncancer patients reporting fatigue. Cortisol, interleukin
(IL)-1B, IL-6, IL-8, neopterin, tumor necrosis factor-, tes-
tosterone, and tryptophan were measured as potential biomar-
kers of fatigue. Tryptophan levels increased with fatigue in
all patients (p  0.05), whereas neopterin levels increased
with fatigue only in patients with cancer (p  0.05). No
significant trends were seen between fatigue and the remain-
ing potential biomarkers. More work needs to be done to
understand the significance of these findings to improve
cancer-related fatigue.
Pain, emotional distress, anemia, sleep disturbances, nu-
tritional deficiencies, medications, comorbidities, and decreased
activity level can contribute to fatigue.12 Psychostimulants, such
as methylphenidate, have been suggested as treatment options in
various practice guidelines.10,12,13 Long-acting methylphenidate
for cancer-related fatigue was studied by Barton et al.14 In their
trial, adult patients with cancer-related fatigue were randomized
to either 54 mg daily of extended release methylphenidate or
placebo. The primary end point was an area under the curve
comparison over 4 weeks of patients’ response when asked to
rate their fatigue per the Brief Fatigue Inventory. Responses
could range from 0, meaning no fatigue, to 12, meaning terrible
fatigue, over the past 24 hours. Sixty-four patients per arm
provided 80% power to detect an effect size of 50% times the
standard deviation. One hundred forty-eight patients were en-
rolled. At the end of 4 weeks of treatment, there were no
significant differences between groups for usual fatigue (p 
0.317). Notably, significantly more patients receiving methyl-
phenidate reported increased nervousness and decreased appetite
during treatment.
In an attempt to identify patient-specific factors associated
with response to methylphenidate for cancer-related fatigue,
Yennurajalingam et al.15 reviewed patients who received meth-
ylphenidate as part of two prospective clinical trials at their
institution. Baseline patient characteristics, symptoms, and re-
sponse at the end of the first day of treatment were analyzed to
determine their association with response to methylphenidate. A
total of 82 patients with advanced cancer received methylpheni-
date, and 61% were responders at day 8 of treatment. Of the
77% of patients who responded after 1 day of treatment, 67%
also demonstrated continued response at day 8 (p  0.03).
Higher baseline fatigue intensity was positively correlated with
response to methylphenidate (p 0.0009). These data suggest a
possible role for methylphenidate in patients with cancer-related
fatigue, particularly for those with advanced disease, poor per-
formance status, and significant baseline fatigue who may oth-
erwise be denied additional treatment. Although methylpheni-
date seems to be of no significant benefit in an unselected group
of patients with cancer-related fatigue, it is conceivable that
some select subpopulations of patients may benefit from this
approach.
Two studies examined the effects of complementary
therapies on cancer-related fatigue. The first was a random-
ized, placebo-controlled trial that evaluated coenzyme Q10’s
(CoQ) effects on self-reported fatigue, depression, and qual-
ity of life.16 Newly diagnosed patients received either 300 mg
CoQ orally or placebo, each combined with 300 international
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units of vitamin E, divided three times daily for 24 weeks.
There were no significant differences for the 236 women
enrolled between the CoQ and placebo arms on the Profile of
Mood States Fatigue (p  0.27) or Functional Assessment of
Chronic Illness Therapy Fatigue (p  0.77) scales. The
second study randomized 75 patients with progressive fatigue
after their first cycle of chemotherapy to either guarana
extract 50 mg orally twice daily (N  32) or placebo (N 
43).17 Guarana (Paullinia cupana) is an Amazonian plant that
has been used as a stimulant since pre-Columbian times. The
extract significantly improved the FACIT-F global scores
compared with placebo on days 21 and 49 (p  0.0004 and
p  0.022, respectively). Guarana was not associated with
any common terminology criteria for adverse events grade 3
or 4 toxicities and did not worsen sleep quality. Although the
studies presented earlier in the text are intriguing, there is a
fundamental lack of understanding of the underlying mech-
anistic factors leading to fatigue associated with cancer.
CANCER PAIN
Greater than 70% of patients with cancer experience pain
at some point during their illness.18,19 In patients with lung
cancer, bone pain is the most common symptom resulting from
bone metastases.20 Bone pain is also a common side effect of
granulocyte-colony stimulating factors. After pegfilgrastim ad-
ministration, however, many patients will experience significant
bone pain for several days. Kirshner et al.21 randomized 510
patients to receive either naproxen 500 mg twice daily or
placebo for 5 to 8 days after their pegfilgrastim injection. During
the 5-day study period, area under the curve for pain was
significantly lower in the naproxen group (6.0 versus 7.7; p 
0.037) as was the incidence of pain (65.6% versus 76.3%; p 
0.01) The duration of pain was also significantly lower in the
naproxen group (1.92 versus 2.40 days; p  0.005) No adverse
events were reported on either study arm. Although naproxen
reduced the incidence, severity, and duration of pegfilgrastim
induced bone pain, a significant proportion of patients taking
naproxen still suffered from bone pain.
Breakthrough cancer pain is often difficult to treat with
oral medications due to their slow onset of action. Two studies
addressed the efficacy of and patient satisfaction with an inves-
tigational fentanyl pectin nasal spray (FPNS). The spray has a
rapid onset of action compared with oral breakthrough pain
medications. Fallon et al.22 compared FPNSwith oral immediate
release morphine sulfate in 84 patients on a stable long-acting
pain regimen experiencing 1 to 4 breakthrough episodes of pain
per day. FPNS use resulted in a statistically significant decrease
in pain intensity at 15 minutes (p  0.05). This resulted in an
overall increase in satisfaction of pain control. Burton et al.23
further examined the long-term safety and tolerability of FPNS
in 403 patients with cancer-related pain. The median duration of
treatment was 60 days. Adverse effects were mild to moderate
and typical of all opioids. After 12 weeks of therapy, approxi-
mately 97% of patients were satisfied with the ease of use and
efficacy of the nasal spray.
THROMBOSIS
Patients with cancer have a sevenfold increased risk of
developing venous thromboembolic events (VTEs).24 The
greatest incidence is seen in patients with aggressive, fast
growing cancers and in those with metastatic disease at
diagnosis. In addition, the risk of VTE recurrence is three
times higher in this population.25 Studies have shown that
patients with lung cancer have a relative risk for VTE of 1.13
(95% CI, 1.07–1.19), when compared with patients without
cancer.26 Many patients with lung cancer have comorbidities,
such as chronic lung disease and/or heart failure, which also
increase the risk of VTE.27
Patients with cancer receiving cytotoxic chemotherapy
have a two to sixfold increased risk of VTE in patients with
cancer receiving chemotherapy, when compared with patients
with cancer not receiving chemotherapy.28 Antiangiogenic
agents are associated with a particularly high rate of thrombosis;
the incidence of thrombosis in patients receiving bevacizumab is
approximately 12%.29 Patients with cancer often require central
venous catheter placement for chemotherapy administration.
Central venous lines are associated with a significant risk of
catheter-associated thrombosis secondary to vessel wall damage
and/or blood stasis.26 Whether the technique of port placement
has any effect on subsequent development of catheter-related
thrombosis had not been well studied.
This year at ASCO, a randomized, prospective study
was presented in which adult patients with solid tumors
eligible for central venous access were randomized to either
a surgical chest port or venography-guided arm port insertion.
The primary objective of the study was to estimate the overall
incidence of VTE and to study risk factors for CVC-related
thrombosis.30 Patients with a previous VTE or ipsilateral
venous catheter or pacemaker, ipsilateral central venous com-
pression/irradiation, poor performance status, or who were
receiving anticoagulation were excluded. Two hundred fif-
teen patients were enrolled over 3 years; 106 patients (49.3%)
received a surgical chest port, and 109 patients (50.7%)
received a venography-guided arm port. Thirty-eight patients
(17.7%) developed a VTE, and 66% of these were CVC-
related thromboses. The CVC-related VTE rates were similar
for both groups (p  0.48). The highest risk was seen in
patients with breast tumors and those with higher stage of
disease at the time of presentation.
In several randomized controlled trials of prophylactic
anticoagulation, the incidence of CVC thrombosis is 5 to 18%
in patients receiving prophylaxis and 4 to 62% in the groups
that do not receive prophylaxis. There is growing evidence
that treatment with an 3-hydroxy-3-methyl-glutaryl coen-
zyme A reductase inhibitor (statin) protects against thrombo-
sis through improving endothelial dysfunction, increased ni-
tric oxide bioavailability, inhibition of the inflammatory
response, and profibrinolytic and antiplatelet effects.31 Statins
have recently been shown to significantly reduce the occur-
rence of symptomatic VTE.32 Giever et al.33 conducted a
study this year to evaluate the effect of statin use on the
incidence of VTE in patients with cancer. They performed a
chart review of 1175 patients with cancer at the Milwaukee
Veterans Affairs hospital who developed a VTE in 2006 and
2007. The incidence of VTE was 4.7% in those patients
undergoing statin therapy and 10.2% in those not on statin
therapy (p  0.001). Twenty-eight (12%) of the 235 patients
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with lung cancer developed VTE, with 16% VTE rate in
patients who were not on statin therapy and 5.5% in patients
taking statins. A subgroup analysis was limited to the patients
with lung cancer only due to the small number of VTEs in the
other groups (Table 1). In this group, findings were consistent
(p  0.016). These results need to be interpreted with
caution, as often patients with early-stage disease continue
health maintenance measures including statin therapy,
whereas patients with advanced cancer are often taken off
drugs such as statins to minimize side effects and simplify
drug regimens. Disease stage could be a possible confound-
ing factor, as it may be that patients taking statins in this
study had earlier stage disease, when compared with patients
who were not taking statins. Prospective validation of the
beneficial effects of statins for patients with cancer should be
confirmed in larger randomized studies before incorporation
into routine clinical practice.
The randomized Comparison of Low Molecular Weight
Heparin versus Oral Anticoagulant Therapy for the Prevention
of Recurrent Venous Thromboembolism in Patients with Cancer
trial demonstrated that dalteparin was more effective than war-
farin in reducing the risk of recurrent VTE. This trial also
showed no additional bleeding risk with dalteparin compared
with warfarin.34 At ASCO this year, Simons et al.35 presented
the results of a retrospective analysis of the effectiveness of
dalteparin in routine clinical practice. Commercial claims data
from January 1, 2004, to December 31, 2008, was reviewed to
identify patients with cancer with a diagnosis of VTE. Inpatient
admissions associated with International Classification of Dis-
eases, Ninth Revision, codes for a primary or secondary diag-
nosis of VTE, following an index VTE, were considered recur-
rent events. Of the 27,245 patients identified, 253 were treated
with dalteparin and 12,453 were treated with warfarin. Patients
treated with dalteparin had a recurrence rate of 2.77% compared
with 6.26% for those receiving warfarin (p  0.0009). The rate
of major bleeding events was 4.74% for the dalteparin group and
8.26% for the warfarin group (p  0.0096). Similar to the
Comparison of Low Molecular Weight Heparin versus Oral
Anticoagulant Therapy for the Prevention of Recurrent Venous
Thromboembolism in Patients with Cancer trial, dalteparin was
shown here to result in a lower rate of VTE recurrence without
increasing the risk of bleeding (Table 2).
COMPLEMENTARY AND ALTERNATIVE
MEDICINE
Patients with cancer often look to complementary and
alternative medicine (CAM) to augment their cancer treat-
ment, treat side effects, or reduce recurrence risk. The inci-
dence of patients using CAM is often underestimated.4,36 In a
recent trial conducted by Micke et al.,5,37 it was determined
that 54% of patients with lung cancer were using some form
of CAM. The majority of patients were using CAM to stop
their tumor from growing. Stephen et al.36 administered 394
surveys to patients who were enrolled in the Phase I Program
at M. D. Anderson Cancer Center. Of the 309 completed
surveys, 52.4% used one or more types of CAM. For the
patients who used CAM, 76% used pharmacologic CAM,
70% used nonpharmacologic CAM, and 47% used both
modalities with significantly more utilization among female
patients. Notably, the majority of patients reported that they
spoke to their physicians about their CAM utilization.
As practitioners are becoming increasingly aware that
their patients are using CAM therapy, it is important to assess
oncologists’ knowledge and practice patterns regarding CAM
therapy. Lee et al.37 surveyed 1000 U.S. oncologists about
their clinical approach to herbal therapy. Of the 423 surveys
returned, 41% of oncologists reported talking with patients
about herbal supplements. When asked about recommenda-
tions of herbal medications, 20% of oncologists recom-
mended use of herbal supplements, whereas 11% often
discouraged the use of herbal supplements. These recommen-
dations were highly dependent on the curability of the cancer:
81% would discourage use with a curable cancer, whereas
37% would discourage use with an incurable cancer. Almost
two thirds of the oncologists stated that they did not have
sufficient knowledge about herbal supplements to answer
questions adequately. Physicians should be aware of this
widely prevalent practice among patients. The impact of
CAM on the pharmacokinetics and pharmacodynamics of
chemotherapeutic agents has not been well studied.
TABLE 1. Subgroup Analysis of Patients with Lung Cancer
on Statin Therapy vs. Those Not on Statin Therapy
Statin
Negative Positive Total
VTE
Negative 121 (84.0%) 86 (94.5%) 207
Positive 23 (16.0%) 5 (5.5%) 28
Total 144 91 235
p  0.016. Adapted from J Clin Oncol.33
TABLE 2. Results of CLOT Trial and Trial of Simons et al.
Trial Treatment
CLOT Simons et al.
Dalteparin (336) Warfarin (336) p Dalteparin (253) Warfarin (12,453) p
RVTE (%) 8.04 15.77 0.002 2.77 6.26 0.0009
MBE (%) 6 4 0.27 4.74 8.26 0.0096
CLOT trial and trial of Simons et al.34,35
RVTE, recurrent vascular thrombosis embolism; MBE, major bleeding events; CLOT, Comparison of Low Molecular Weight
Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer.
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SUMMARY
Y Single-dose fosaprepitant is noninferior to 3-day aprepi-
tant in treating CINV.
Y Patients with lung cancer receiving cisplatin who re-
ceive palonosetron antiemetic therapy have a lower risk
of CINV than patients receiving other 5-HT3 antagonist-
based antiemetic regimens.
Y Olanzapine may be useful in the treatment of CINV in
patients receiving cisplatin or doxorubicin.
Y Tryptophan and neopterin may be markers of cancer-
related fatigue.
Y Guarana may improve cancer-related fatigue.
Y Patients receiving pegfilgrastim should receive naproxen
to reduce the incidence and duration of pelfilgrastim-
induced bone pain.
Y FPNS is an effective medication for the treatment of
breakthrough cancer pain.
Y Statins may possibly decrease the incidence of VTE in
patients with cancer and may also provide a survival
benefit.
Y In patients with cancer, use of dalteparin results in a
lower rate of VTE recurrence than warfarin, without
increasing the risk of bleeding.
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